Clinical Trial Update: PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating a PD-1 antibody combined with apatinib mesylate for serum AFP-elevated gastric adenocarcinoma after 2+ lines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib Mesylate (apatinib)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: China Medical University, China | Conditions: Gastric Cancer, AFP | Phase 2 | Status: UNKNOWN